Menna

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Menna

Property Description
Active Ingredient Diphenhydramine Hydrochloride
Form Oral solids, oral liquids, injection solutions
Pharmacological Class First-Generation H₁ Receptor Antihistamine
Origin Synthetic Compound
General Purpose Relief of symptoms associated with histamine release and sedation

Menna is a brand-name pharmaceutical preparation that contains the active ingredient Diphenhydramine Hydrochloride, which is classified pharmacologically as a First-Generation H₁ Receptor Antihistamine. This compound is the result of synthetic chemical synthesis and belongs to the ethanolamine class. The drug's unique positioning is based on its classification; unlike newer agents, its chemical structure enables the molecule to easily penetrate the blood-brain barrier.

Mechanism and General Purpose of Diphenhydramine

The core component of Menna acts by engaging in competitive antagonism at the body's histamine H₁ receptors, thereby preventing histamine from binding and exerting its effect. This primary action, combined with its secondary anticholinergic action (influencing the neurotransmitter acetylcholine), defines its pharmacological profile. Consequently, the preparation inherently possesses a pronounced sedating capability in addition to its primary action. This sedative property has been clinically recognized for its efficacy in a common use scenario, specifically providing short-term assistance for individuals needing to establish rest when a calming effect is beneficial.

Summary of Benefits

The general benefit for this compound stems directly from its dual pharmacological actions: relieving symptoms mediated by histamine release and leveraging its sedative properties. The preparation is thus generally utilized to address the discomforts associated with excessive histamine activity. These core actions define the scope of the drug’s potential applications at a fundamental level, including promoting rest and sleep, or addressing general discomfort related to motion. Menna is often positioned for adult use and is typically available over-the-counter (OTC).

What side effects are possible with Menna?

The safety profile for Menna (Diphenhydramine Hydrochloride) is characterized by effects categorized by frequency and the body systems involved, as documented in official regulatory labeling.

Adverse Reactions and Classification

Adverse reactions are formally grouped into System-Organ-Classes, including Nervous System Disorders, Gastrointestinal Disorders, and Cardiovascular Disorders. The most frequently listed effects are those officially classified as Common, which include drowsiness (somnolence), dryness of the mouth, nose, and throat, dizziness, and fatigue. Reactions categorized as Rare in official documents include specific blood disorders (such as agranulocytosis), confusion, depression, and severe hypersensitivity reactions.

Serious Adverse Reactions and Safety Constraints

The regulatory profile lists serious adverse events, including anaphylactic shock and convulsions. Safety documents from authorities like the FDA have highlighted that high doses carry the risk of severe outcomes, including seizures and serious heart problems.

The drug is officially noted to have additive effects with alcohol and other CNS depressants. Use is contraindicated in neonates and nursing mothers. Older adults are specifically noted as being more likely to experience sedation, dizziness, and hypotension. In pediatric patients, the drug may cause the opposite of sedation, resulting in paradoxical excitation or restlessness.

Overdose and Emergency Response

Overdose and when to seek help — official regulatory information for Menna

Overdose scope

Property Description
Documented overdose presentations Overdose may present with serious CNS symptoms, including agitation, delirium, seizures, coma, and excessive drowsiness. Anticholinergic effects such as inability to urinate (urinary retention), enlarged pupils (mydriasis), and hyperthermia are also documented clinical signs.
Physiological systems affected Central Nervous System (CNS), Cardiovascular System.
Dose-related or exposure-related factors Pediatric ingestion exceeding approximately 7.5 mg/kg warrants specific medical evaluation.
Population-specific overdose notes Increased risk of serious outcomes, including death, is officially documented in children.
Emergency-response statements Seek immediate medical attention (or call emergency services) and contact the Poison Help hotline immediately.
When immediate medical help is required If the person has a seizure, has trouble breathing, exhibits hallucinations, or cannot be awakened (loss of consciousness).

Overdose classifications (high-level)

Property Description
Severity classification Potential for Life-Threatening outcomes including Cardiac Arrest and Respiratory Failure.
Regulatory basis Based on official prescribing information from government authorities.
Overdose-context constraints Management must be symptomatic and supportive; the guidance confirms no specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • Manifestations include serious Heart Rhythm Problems (Arrhythmias) and documented QRS widening.
  • Management involves required Constant Cardiac Monitoring (ECG/EKG) and the use of Sodium Bicarbonate for cardiac toxicity.

Connection to the overall overdose profile

Regulatory documents define the overdose profile by the potential for severe CNS and critical cardiovascular effects. These official manifestations establish the immediate and non-negotiable requirement to seek emergency medical attention as the only course of action. The regulatory guidance confirms that care is symptomatic and supportive, necessitating mandatory hospital monitoring procedures.

Therapeutic Uses of Menna

What Menna Treats: Main Uses and Benefits

Menna is applied across domains where additional symptomatic support is needed, generally addressing symptoms related to heightened physiological activity. The preparation is commonly used to help with several symptomatic domains.


The preparation is relevant for easing certain distressing symptoms associated with irritative states, such as those during acute episodes of allergic distress, and is commonly used for managing conditions where symptoms create noticeable functional strain, such as temporary difficulty with falling asleep. It is also applied in managing symptoms of motion-induced discomfort, and is considered relevant within clinical settings that involve acute or unstable symptom patterns, such as when supportive symptom management is appropriate during transfusion procedures.

The medication helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort (sneezing, runny nose, itching, nausea) and symptoms associated with acute or episodic changes (episodic sleeplessness). This contributes to improved comfort during periods of heightened symptoms and supports general comfort during phases where symptoms are more noticeable.

“Applied in situations where patients experience temporary symptom patterns, the preparation provides supportive relief.”


Therapeutic Focus: Symptomatic Relief

Quick Fact: Relief for Allergic Symptoms Menna is commonly used across conditions presenting with acute episodes of allergic distress, and assists with easing the overall symptom load related to itching and runny nose (rhinorrhea).

Regulatory References

  1. NIH MedlinePlus overview of Diphenhydramine

Eligibility and Restrictions for Use

Eligibility Scope and Restrictions

Menna (Diphenhydramine HCl) eligibility is strictly defined by regulatory documents, prohibiting use in certain populations and requiring caution in others. The medicine is generally approved for adults and pediatric patients aged 2 years and older for indicated conditions. Children under 2 years must not use this medicine.

Absolute Contraindications

Use is contraindicated and formally prohibited in the following groups:

  • Patients with known hypersensitivity to Diphenhydramine Hydrochloride.
  • Neonates or premature infants.
  • Nursing mothers, due to the potential for higher risk to the infant.

Populations Requiring Caution

Official labeling requires that the medicine be used with considerable caution in patients with specific pre-existing conditions, primarily due to its anticholinergic properties:

  • Conditions such as narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction.
  • Patients with renal or liver disease due to the risk of drug accumulation.
  • Older adults (approximately 60 years or older) are more likely to experience adverse effects such as sedation and dizziness. Caution is required in patients with cardiovascular disease or hypertension.

Pregnancy Status

During pregnancy, the drug should be used only if clearly needed, according to official labeling. Use during lactation is listed as a formal contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Menna (Diphenhydramine) has officially documented interactions primarily centered on its core pharmacological effects.

Interaction Scope

Categories with Documented Interactions Specific Agents Listed in Regulatory Documents
Central Nervous System (CNS) Depressants Alcohol
Anticholinergic Drugs Monoamine Oxidase Inhibitors (MAOIs)

Mechanistic Basis of Interactions

Regulatory documents state that co-administration with Alcohol and other CNS depressants results in additive CNS depressant effects. This means the combined effect on the central nervous system is greater than either substance alone. Furthermore, the drug has additive anti-muscarinic action with other anticholinergic drugs, and MAO Inhibitors are noted to prolong and intensify these specific effects.

Population-Specific Interaction Notes

Interactions that increase CNS depression are of greater concern in certain groups. Elderly patients (60 years and older) are officially noted as more likely to experience enhanced sedation, dizziness, and hypotension from antihistamines. Additionally, caution is noted regarding systemic exposure in patients with hepatic impairment, as the drug is extensively metabolized in the liver.

Connection to the overall interaction profile

The official interaction profile is structured by pharmacodynamic reinforcement, detailing how the drug's properties lead to intensified effects when co-administered with substances sharing CNS depressant or anticholinergic activities. These documented additive effects form the basis for regulatory statements concerning co-use and specific population considerations.

Mechanism of Action

Targeted Receptor-Mediated Signaling Modulation

Menna modulates key pathways by acting within domains that involve specific receptor-mediated signaling. This action affects systems where particular transmitters or mediators dominate, initiating signaling sequences that shape systemic physiological outcomes.


Influence on Specific Molecular Targets

The drug engages mechanisms that govern specific signaling patterns within the biological system. By modifying early molecular steps, Menna alters the basal activity level of targeted pathways, which reduces the concentration or activity of specific mediators.


Pathway Feedback Regulation and Response Attenuation

Menna is active in systems which involve targeted pathway modulation by influencing feedback regulation within cascades. This leads to predictable physiological adjustments that result in an attenuation of pathway-driven physiological responses, thus defining the scope of the drug's activity.

Dosage and Administration Information

Menna (Diphenhydramine HCl) is administered according to standardized regimens. The compound is officially delivered via multiple routes, primarily oral for general symptomatic use, but also intramuscular (IM) and intravenous (IV) injection, and topically. The choice of route is defined by the required speed of action and the clinical context, not the user's preference.

Standard adult dosing for antihistaminic use is typically between 25 mg and 50 mg per dose, with the option to repeat the dose every four to six hours as required. The maximum daily intake is generally capped at 300 mg. When used for temporary difficulty sleeping, the standard adult regimen is a single 50 mg dose taken once at bedtime. For parenteral administration (IM or slow IV), the starting range is often lower, from 10 mg to 50 mg, with the requirement that the intravenous infusion rate must not exceed 25 mg per minute.

Specific administration instructions govern proper use. Liquid forms must be measured using a calibrated dosing device rather than uncalibrated household implements. For pediatric administration, dosing follows weight-based calculations, adhering strictly to the maximum approved daily dose. A lower starting dose may be necessary for older adults due to potential increased sensitivity to the compound. The drug is intended for short-term symptomatic management and is not indicated for long-term chronic use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Menna


Evidence for Symptom Relief in Acute Allergic Distress

Research examining the compound's evaluation in clinical studies for acute allergic symptoms includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies have primarily focused on adults and adolescents experiencing conditions characterized by heightened symptom activity, such as seasonal allergic rhinitis or acute urticaria (hives). Studies monitored specific outcomes related to physical discomfort, including Total Symptom Scores (TSS). Findings describe changes measured in symptom scores over short, defined time intervals, which contributes to understanding symptom patterns during the most noticeable phases of an allergic episode.


Evidence for Short-Term Difficulty with Falling Asleep

Research for the compound's use in occasional sleeplessness has been conducted using controlled research, including double-blind, placebo-controlled RCTs designed to explore short-term changes in sleep parameters in adults. Primary outcomes monitored included Sleep Latency (time to fall asleep). Studies monitored changes in measured Sleep Latency compared to a placebo, with findings describing differences during the initial days of use. However, research highlights that tolerance to the compound's sedative properties was observed to develop quickly, with evidence suggesting that these measured changes may not be sustained beyond one or two weeks of continuous use.


Research on Outcomes in Different Age Groups and Gaps

Studies have monitored the use of the compound in older adult populations, noting that the compound may be associated with changes in daily functioning. The evidence contributes to understanding symptom patterns in older adults, highlighting a limitation in the applicability of the findings for routine use in this group. Similarly, data for certain groups remain insufficient, particularly in very young children, where research describes that in some cases, children may experience an unexpected change in activity level instead of sedation, making study findings for this group highly variable. Comparative evidence is lacking in modern, large-scale head-to-head trials against newer antihistamines, limiting the ability to fully contextualize the compound's activity profile today.

Key Studies & References

  1. MedlinePlus: Diphenhydramine (Oral Route)

Frequently Asked Questions (FAQ)

Common questions about Menna (FAQ)

Q: How long does it typically take for Menna to start working?

A: According to official regulatory information, the oral forms of the active ingredient in Menna typically begin to work within about 30 minutes. The peak effects are generally reached within one to two hours. The time it takes to notice effects may vary between individuals.

Q: Is Menna meant for short-term or long-term use?

A: Official labeling indicates that Menna is intended for short-term symptomatic use. Continuous long-term use is not typically recommended because tolerance to the drug's sedative effect can develop quickly. Long-term use is generally associated with potential risks, particularly in older adults.

Q: Is it normal to feel a mild headache after starting Menna?

A: Regulatory documents list common side effects such as drowsiness and dry mouth. While headache is not always categorized as a common side effect, it has been reported by some users taking the active ingredient in Menna. If concerning or severe effects, such as headaches, occur, consult the official product information.

Q: Is it safe to take Menna with birth control pills?

A: Regulatory interaction checks for the active ingredient in Menna typically show no known interaction with common oral contraceptive pills. However, users are generally advised to review all current medications with a healthcare professional.

Q: What types of foods or supplements should be avoided when taking Menna?

A: The primary official warning concerns avoiding alcohol and other medicines that cause central nervous system (CNS) depression, as these can increase Menna's sedative effects. Warnings about specific food interactions are not universally listed. It is important to review the use of any supplements with a healthcare professional.

Q: What is the typical duration of treatment with Menna?

A: The active ingredient in Menna is generally intended for temporary relief. For instance, it is often used for up to 7 days for certain allergic symptoms or for occasional sleeplessness. This aligns with its positioning for short-term symptomatic relief.

Q: Can children or adolescents be prescribed Menna?

A: Official information states that the drug is approved for pediatric patients aged 2 years and older for the indicated conditions. Dosing is often weight-based for children, and the medication is included in guidance for use by adolescents.

Q: Can Menna cause changes in appetite or weight?

A: Changes in appetite, including both decreased appetite (anorexia) and increased appetite, have been reported as side effects of the active ingredient in Menna. These effects are not typically listed among the most common adverse reactions.

Q: Is Menna an anti-inflammatory medication?

A: Menna is primarily classified as a First-Generation H₁ Receptor Antihistamine. Its main actions are blocking histamine and providing sedation, and it is not classified or indicated as a primary anti-inflammatory agent.

Q: Can Menna affect blood pressure or heart rate?

A: Yes, official regulatory documents list possible cardiovascular side effects. These can include hypotension (low blood pressure) and changes to heart rhythm or rate (palpitations), which are particularly noted with higher doses or in sensitive populations.

Q: Can Menna be taken with milk or food to reduce stomach irritation?

A: While specific administration instructions on taking Menna with food or milk are not universally present, taking the medication with food may help to lessen common gastrointestinal side effects like stomach upset. Administration details, including whether to take with food, should be based on the specific product information.

Q: Are there any serious side effects of Menna that require immediate medical attention?

A: Yes, official safety documents highlight rare but serious adverse reactions, including convulsions (seizures), severe heart problems, and anaphylactic shock (a severe allergic reaction). Official safety information notes that severe reactions warrant immediate medical attention.

Q: Can Menna cause insomnia or restlessness?

A: Although Menna is known for causing sedation, some individuals, particularly children, may experience the opposite effect, which is known as paradoxical excitation or restlessness. Insomnia has also been reported as an adverse effect in adults.

Q: How quickly does Menna leave the system after stopping treatment?

A: The active ingredient has an elimination half-life, which describes the rate at which the body removes the drug. It takes a period of time for the body to fully clear the medication, and this timeframe can vary widely between individuals.

Q: Is Menna available as a generic drug?

A: Yes, the active ingredient in Menna, Diphenhydramine Hydrochloride, is a well-established compound that is widely available in many generic and store-brand formulations worldwide.

Q: Can Menna affect one's ability to drive or operate machinery?

A: Official warnings state that due to common side effects such as drowsiness, dizziness, and decreased coordination, caution should be exercised. Due to the risk of drowsiness, official warnings suggest caution regarding driving or operating complex machinery.

Q: What are the ingredients in Menna besides the active compound?

A: All formulations of Menna contain both the active compound (Diphenhydramine Hydrochloride) and inactive ingredients, or excipients. The specific list of inactive ingredients varies depending on the product form and the specific manufacturer.

Q: Does the efficacy of Menna decrease over time?

A: Studies and official information indicate that a rapid tolerance to the drug’s sedative property can develop. This suggests that the measured effects on sleep may not be sustained beyond one or two weeks of continuous use.

Q: Is Menna known to cause mood changes or depression?

A: Regulatory documents list depression and confusion among the possible adverse reactions to the active ingredient, though these effects are classified as rare. If concerning effects such as mood changes or confusion occur, users should refer to their official product information.

Q: What population groups have the most robust evidence for Menna's effectiveness?

A: Clinical studies supporting the compound's official indications have primarily focused on adults and adolescents. Evidence is strongest for adults experiencing occasional sleeplessness and both adults and adolescents with acute allergic symptoms.

Q: Can Menna be crushed or split if it's difficult to swallow?

A: Standard tablets are generally intended to be swallowed whole. Specific dosage forms, such as extended-release products, must not be crushed, split, or chewed, as this can affect how the drug is absorbed and may increase the risk of side effects.

Q: Is Menna a controlled substance?

A: The active ingredient in Menna, Diphenhydramine Hydrochloride, is not scheduled as a federally controlled substance in the United States. It is widely available over-the-counter.

Q: What does the latest research suggest about the long-term safety of Menna?

A: Long-term, continuous use of the active ingredient and other first-generation antihistamines is generally discouraged. Due to potential side effects and the development of tolerance, official guidance often suggests avoiding long-term, routine use, particularly in older adults.

Q: Does Menna have any potential for misuse or dependence?

A: Official information indicates that while the active ingredient is not a controlled substance, there have been documented reports of misuse and the potential for psychological dependence associated with its consumption.

Q: Are there any specific lifestyle changes recommended while taking Menna?

A: Official warnings recommend caution regarding activities that require high mental alertness. Due to the risk of drowsiness, it is advised to exercise caution with activities like driving or operating heavy machinery.

Q: Are there different formulations or strengths of Menna available?

A: Yes, the active ingredient is available in various forms to suit different needs. These include oral tablets, capsules, liquids, and injectable solutions, each offered in different milligram strengths.

Q: What should be done if an adverse reaction to Menna occurs?

A: Official guidance recommends reporting side effects to a healthcare provider and the national drug authority (e.g., FDA MedWatch). Serious reactions, such as difficulty breathing or swelling, warrant immediate medical attention.

Q: Do people need regular blood tests while on Menna?

A: Regulatory documents do not typically mandate routine blood tests for the average user taking Menna for its approved indications. However, certain rare blood disorders are listed as possible adverse effects.

Q: Is Menna used to treat both acute and chronic conditions?

A: The drug is officially indicated for the temporary relief of acute symptoms, such as those associated with seasonal allergies or occasional difficulty sleeping. It is not generally intended for the routine, long-term management of chronic health conditions.

How should Menna be stored and disposed of?

Official Storage and Disposal Requirements

Requirement Type Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, 20 to 25 C (68 to 77 F), with permitted excursions to 30 C (86 F).
Environmental Protection The product must be protected from freezing and light. Avoid excess heat and moisture.
Container Requirements Keep the medication in its original container, tightly closed. For injectable solutions, retain in the carton until time of use.
Child Safety Keep out of the reach and sight of children. Store the medicine up and away in a safe location.
Disposal Instructions Dispose of any unused product in accordance with local requirements. Do not flush the product down the toilet unless specifically instructed. Utilize drug take-back programs when available, or mix with an undesirable substance (e.g., dirt) for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Menna found in:

A-Z Index: